New Issue: Science’s Impossible Questions. Read Now

New Approach Could Allow Doctors to 'See' Alzheimer's with MRIs

Join Our Community of Science Lovers!


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Scientists have successfully used magnetic resonance imaging (MRI) to identify the destructive brain legions that cause Alzheimer¿s disease in mice. If the results can be replicated in people, they could point to a diagnostic test for an ailment that currently afflicts nearly 4.5 million Americans.

The amyloid plaques that are a hallmark of Alzheimer¿s disease can currently be identified only during an autopsy, although patients are diagnosed with the disease on the basis of behavioral observations. Joseph Poduslo of the Mayo Clinic School of Medicine and his colleagues manufactured a novel molecular probe that targets plaques in the brains of laboratory mice and allows them to show up on a standard MRI scan. "A simple MRI evaluation for Alzheimer¿s disease would ease the suffering of so many families and, hopefully, vastly improve patient-care options," Poduslo remarks. The probe--a molecule that is derived from the protein that causes the plaques in humans--was able to cross the blood-brain barrier and attach to the amyloid plaques in the brains of mice. Most important, it also provided enough visual contrast to produce high-resolution MRI images while the animals were alive. The findings were published online on Friday by the journal Biochemistry.

The researchers also tested the new probe on tissue donated by patients who had succumbed to Alzheimer¿s. Although the molecule behaved differently in human brains than it did in those of mice, the probe successfully labeled the plaques. Further research is needed to determine whether the approach will work for human patients, but the authors note that their results could allow for early diagnosis and offer a way to monitor the disease's progression as well as the efficacy of current therapies.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe